Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05649748 · ClinicalTrials.gov registry record · Phase 2

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

A Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Insmed Incorporated.

Active
Registry status
Phase 2
Development phase
91
Enrollment target
20
Study locations

NCT05649748 is a Phase 2 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Insmed Incorporated. The registered enrollment target is 91 participants, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05649748, a Phase 2 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Insmed Incorporated.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
91 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.

Conditions Studied

Pulmonary Arterial Hypertension

Interventions

  • DRUG Placebo
  • DRUG Treprostinil Palmitil

Study Locations (20)

Other

  • ARG004 - Córdoba
  • ARG001 - Córdoba
  • AUT001 - Vienna
  • BEL003 - Brussels

Florida

  • USA005 - Jacksonville
  • USA011 - Tampa

Illinois

  • USA006 - Chicago
  • USA001 - Chicago

New York

  • USA102 - New York

Texas

  • USA016 - Dallas

Buenos Aires

  • ARG009 - Quilmes

Santa Fe Province

  • ARG006 - Rosario

Tucumán Province

  • ARG007 - San Miguel de Tucumán

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2023-03-07
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Insmed Incorporated

31 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05649748

The ClinicalTrials.gov registry entry for NCT05649748 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (80% lower). The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05649748 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05649748 about?

NCT05649748 is a clinical study titled "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)". The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.

What is the current status of trial NCT05649748?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2023-03-07. Estimated completion is 2026-12-31.

What conditions does trial NCT05649748 study?

This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.

What interventions are being tested in trial NCT05649748?

The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil (DRUG).

Who is sponsoring clinical trial NCT05649748?

This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05649748 being conducted?

This trial has 20 study locations across Florida, Illinois, New York, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Arterial Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Arterial Hypertension

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.